EDAP:NASDAQEDAP TMS S.A. Analysis

EDAP TMS SA trades at $3.58, well below its 20‑day SMA (3.95) and 50‑day SMA (4.18), with RSI at 38 and a bearish MACD, indicating short‑term downside pressure but also proximity to a key support level around $3.10. Despite a 19% revenue decline and negative margins, the company reported a record 39% YoY growth in its HIFU segment, and analysts project a median target of $4.00 with a potential upside of over 90%.
The balance sheet shows high leverage (debt‑to‑equity ~143%) and negative cash flows, while the stock exhibits high 30‑day volatility (~53%) and a beta near 1, suggesting market‑wide risk exposure. The upcoming Q4/2025 earnings release and investor presentations will be pivotal in confirming whether the HIFU momentum can translate into improved profitability and a healthier financial profile.